Posted by Michael Wonder on 14 Feb 2021
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
12 February 2021 - The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity.
Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021.
Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.
